PL366223A1 - Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof - Google Patents

Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Info

Publication number
PL366223A1
PL366223A1 PL01366223A PL36622301A PL366223A1 PL 366223 A1 PL366223 A1 PL 366223A1 PL 01366223 A PL01366223 A PL 01366223A PL 36622301 A PL36622301 A PL 36622301A PL 366223 A1 PL366223 A1 PL 366223A1
Authority
PL
Poland
Prior art keywords
epitopes
antibodies
isolated molecules
containing sulfated
sulfated moieties
Prior art date
Application number
PL01366223A
Other languages
English (en)
Polish (pl)
Inventor
Janette Lazarovits
Yocheved Hagai
Daniel Plaksin
Tikva Vogel
Abraham Nimrod
Hagit Mar-Haim
Ester Szanthon
Tamar Richter
Boaz Amit
Lena Kooperman
Tuvia Peretz
Avigdor Levanon
Original Assignee
Bio-Technology General Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio-Technology General Corp. filed Critical Bio-Technology General Corp.
Publication of PL366223A1 publication Critical patent/PL366223A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL01366223A 2000-12-29 2001-12-31 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof PL366223A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US25894800P 2000-12-29 2000-12-29

Publications (1)

Publication Number Publication Date
PL366223A1 true PL366223A1 (en) 2005-01-24

Family

ID=26946974

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366223A PL366223A1 (en) 2000-12-29 2001-12-31 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Country Status (13)

Country Link
EP (1) EP1406930A4 (cs)
JP (1) JP2005503756A (cs)
KR (1) KR20030091953A (cs)
CN (1) CN100347194C (cs)
BR (1) BR0116764A (cs)
CA (1) CA2433225A1 (cs)
CZ (1) CZ20031982A3 (cs)
HU (1) HUP0700079A2 (cs)
IL (1) IL156689A0 (cs)
MX (1) MXPA03005945A (cs)
PL (1) PL366223A1 (cs)
RU (1) RU2003123101A (cs)
WO (1) WO2002053700A2 (cs)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
CA2491427A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
KR20060107501A (ko) * 2003-06-30 2006-10-13 바이오-테크널러지 제너럴 (이스라엘) 리미티드 특이적인 인간 항체
CN101300021A (zh) * 2003-06-30 2008-11-05 生物技术通用（以色列）有限公司 抗体及其用途
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
BRPI0510561A (pt) * 2004-05-11 2007-11-20 Abgenomics Corp epìtopos que induzem morte de célula t
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
KR102038357B1 (ko) 2012-06-22 2019-10-31 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
WO2016013828A1 (ko) * 2014-07-21 2016-01-28 연세대학교 산학협력단 황산화된 더피 케모카인 수용체의 세포 외 도메인 1 변이체 및 이의 용도
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
JP2019031486A (ja) * 2017-08-04 2019-02-28 公立大学法人福島県立医科大学 新規ポリペプチド及びその用途
CN109929036B (zh) * 2017-12-19 2024-12-03 泰州迈博太科药业有限公司 一种表位特异的抗体筛选方法及所筛选到的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3326693A (en) * 1991-12-12 1993-07-19 Scripps Research Institute, The Bifunctional antithrombotic molecules and antithrombotic polypeptides
JPH11508131A (ja) * 1995-06-14 1999-07-21 ザ ジェネラル ホスピタル コーポレーション Ｐ−セレクチンリガンドおよび関連分子並びに方法
DE69630307T2 (de) * 1995-08-03 2004-07-15 The Board Of Regents Of The University Of Oklahoma, Norman O-glycaninhibitoren von selectinvermittelten entzüngen
US5985833A (en) * 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
DE69934890D1 (de) * 1998-06-16 2007-03-08 Univ Oklahoma Glykosulfopeptide und verfahren zu deren herstellung und deren verwendung

Also Published As

Publication number Publication date
EP1406930A4 (en) 2007-01-10
CN100347194C (zh) 2007-11-07
BR0116764A (pt) 2007-01-09
WO2002053700A2 (en) 2002-07-11
CZ20031982A3 (cs) 2004-09-15
EP1406930A2 (en) 2004-04-14
WO2002053700A3 (en) 2004-02-12
IL156689A0 (en) 2004-01-04
RU2003123101A (ru) 2005-03-10
MXPA03005945A (es) 2004-10-15
CN1649900A (zh) 2005-08-03
KR20030091953A (ko) 2003-12-03
JP2005503756A (ja) 2005-02-10
CA2433225A1 (en) 2002-07-11
HUP0700079A2 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
MXPA03001590A (es) Anticuerpos para la il-1beta humana.
HUP0302128A3 (en) Anti-dual integrin antibodies, compositions, methods and uses
ZA200400521B (en) Antibodies to OPGL.
ZA200207589B (en) Multivalent antibodies and uses therefor. Multivalent antibodies and uses thereof.
TWI316088B (en) Anti-tnf alpha antibodies and their uses
AU3662101A (en) Cd40-binding apc-activating molecules
AU8113701A (en) Anti-il-12 antibodies, compositions, methods and uses
GB0029360D0 (en) Humanised antibodies and uses thereof
HUP0700079A2 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
GB0002093D0 (en) Antiperspirants
AU7522401A (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
AU2002365894A8 (en) Antibodies to magmas and uses thereof
GB0115428D0 (en) Antibodies, peptides, analogs and uses thereof
AU2002221132A1 (en) Novel antibody
GB0022670D0 (en) Molecules
GB0002625D0 (en) Dendroaspin molecules
GB0031284D0 (en) High affinity antibodies
AU8557801A (en) Modified proteins, isolated novel peptides, and uses thereof
GB0020568D0 (en) Novel antibody
AU2001236588A1 (en) Antibodies to the staphylococcal multidrug resistance (smr) protein
GB0005071D0 (en) Antibodies
GB0003527D0 (en) Antibodies
GB0005728D0 (en) Conserved antigens
GB0009538D0 (en) Antibody binding
GB0003359D0 (en) Monoclonal antibodies

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)